Previous 10 | Next 10 |
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its...
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company announced that it has completed enrollment in its phase 2 study of CYB003, a pro...
- Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2 data for pivotal studies - - Breakthrough Therapy designation anticipated in late 2023, subject to FDA approval - - P...
2023-09-20 08:29:39 ET Palm Beach, FL – September 20, 2023 – FinancialNewsMedia.com News Commentary – The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for abuse deterre...
2023-09-19 09:23:45 ET DENVER, Colo., September 12, 2023 ( www.247marketnews.com )- The Legendary Ryan Cohen Strikes Again! A lot of traders are talking about Cybin’s (NYSEAMERICAN:CYBN) SC 13G filing, which revealed the acquisition of a whopping 18,950,000 shares by ...
2023-09-19 08:00:18 ET FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – September 19, 2023 – Depression is costing the economy $1 trillion in lost production every single year. Yet, a classical compound that even the FDA has twi...
2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...
2023-09-14 12:58:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The global inflation surge and monetary policy tightening by major central banks have all contributed to the market volatility this year. Despite that, both the S&P 500 and the Nasdaq indic...
Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has received notification that the United States Patent and Trademark Office (“USPT...
- Newly granted U.S. patent further strengthens the Company’s leadership position in the deuterated tryptamine space - - With the recently announced definitive agreement to acquire Small Pharma Inc. The granted patent will add to the most impressive intellectual property portfolio ...
News, Short Squeeze, Breakout and More Instantly...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases followi...
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser , Cybin highlighted k...